Today: 9 June 2026
Browse Category

NASDAQ:SLS 18 October 2025 - 20 May 2026

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
20 May 2026
·
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

SELLAS Life Sciences (NASDAQ: SLS) shares doubled year-to-date in 2025, closing at $2.14 on Oct. 17 after a 38% after-hours jump and hitting a 52-week high of $2.27. BlackRock disclosed a 5.4% stake in the company. Interim Phase 3 trial results for SELLAS’s lead cancer drug showed median survival over 13.5 months in AML patients. Final trial data is expected by year-end 2025.
18 October 2025

Stock Market Today

  • Analysis Suggests SpaceX IPO May Be Overvalued
    June 8, 2026, 6:56 PM EDT. Despite optimistic projections, SpaceX's initial public offering (IPO) could be overvalued. Evaluations indicate that only the most ambitious 'Moonshot' scenario nearly matches the proposed IPO price, raising concerns about high market expectations. Investors should weigh potential risks given the optimistic forecasts underpinning the valuation.

Latest articles

T1 Energy Shares Dip After KORE Power Files New Update

T1 Energy Shares Dip After KORE Power Files New Update

9 June 2026
T1 Energy shares slid 3.2% to $9.13 after a new SEC filing revealed up to $24.7 million in stock-linked payments for its $32 million KORE Power acquisition, spotlighting dilution risks as the company expands into battery storage and data-center power; the deal’s structure and timing come as T1 seeks growth funding and investors weigh near-term costs against future EBITDA targets.
OpenAI IPO filing puts AI rally at center stage for Wall Street

OpenAI IPO filing puts AI rally at center stage for Wall Street

9 June 2026
OpenAI has confidentially filed for a possible IPO, but investors won’t see key financials—including revenue quality, cash burn, and compute costs—until the S-1 goes public; with $2 billion monthly revenue and a recent $852 billion valuation, the filing signals a pivotal shift as AI giants race for public capital amid rising infrastructure costs and growing competition from Anthropic.
Wall Street Volatility Index Jumps as Chip Stocks Swing

Wall Street Volatility Index Jumps as Chip Stocks Swing

9 June 2026
The VIX plunged 12% to 18.92 as chip stocks rebounded sharply, with the Philadelphia Semiconductor Index jumping 5.6% and Intel soaring 11.2% after a major Google order, clawing back part of Friday’s $1.3 trillion rout; investors remain cautious ahead of key inflation data, interest rate decisions, and Middle East risks.
UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
Go toTop